MyJournals Home  

RSS FeedsPharmaceuticals, Vol. 12, Pages 112: Larvicidal and Enzymatic Inhibition Effects of Annona muricata Seed Extract and Main Constituent Annonacin against Aedes aegypti and Aedes albopictus (Diptera: Culicidae) (Pharmaceuticals)

 
 

26 july 2019 21:03:40

 
Pharmaceuticals, Vol. 12, Pages 112: Larvicidal and Enzymatic Inhibition Effects of Annona muricata Seed Extract and Main Constituent Annonacin against Aedes aegypti and Aedes albopictus (Diptera: Culicidae) (Pharmaceuticals)
 


The mosquitoes Aedes aegypti and Aedes albopictus are vectors of arboviruses that cause dengue, zika and chikungunya. Bioactive compounds from plants are environmentally sustainable alternatives to control these vectors and thus the arboviruses transmitted by them. The present study evaluated the larvicidal activity of an acetogenin-rich fraction (ACERF) and its main constituent annonacin obtained from Annona muricata seeds on Ae. aegypti and Ae. albopictus. The larvicidal assays were performed using different concentrations to calculate the LC50 and LC90 values observed 24 h after exposure to the treatment. Annonacin was more active against Ae. aegypti (LC50 2.65 μg·mL−1) in comparison with Ae. albopictus (LC50 8.34 μg·mL−1). In contrast, the acetogenin-rich fraction was more active against Ae. albopictus (LC50 3.41 μg·mL−1) than Ae. aegypti (LC50 12.41 μg·mL−1). ACERF and annonacin treated larvae of Ae. aegypti and Ae. albopictus showed significant differences in the inhibition of their metabolic enzymes when compared to untreated larvae. The results demonstrate the relevant larvicidal action of the acetogenin-rich fraction and annonacin showing the potential to develop new products for the control of Ae. aegypti and Ae. albopictus.


 
227 viewsCategory: Medicine, Pharmacology
 
Pharmaceuticals, Vol. 12, Pages 111: Special Issue `Targets, Tracers and Translation Novel Radiopharmaceuticals Boost Nuclear Medicine` (Pharmaceuticals)
Pharmaceuticals, Vol. 12, Pages 114: Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy (Pharmaceuticals)
 
 
blog comments powered by Disqus


MyJournals.org
The latest issues of all your favorite science journals on one page

Username:
Password:

Register | Retrieve

Search:

Pharmacology


Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures News Tweets Nachrichten